The Copenhagen-headquartered group is taking its antibody-drug conjugate rinatabart sesutecan into Phase III and chief medical officer Tahi Ahmadi tells Scrip that it has the potential to treat far more women than the only currently marketed FRα-targeting ADC, AbbVie's Elahere.

Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.

While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.

The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?